Tag: Health Care
Displaying 1 - 20 of 1132 results.
Pages
The PNO routinely provides informal guidance on Hart-Scott-Rodino reporting obligations that arise when combining not-for-profit entities, typically in the context of hospital combinations. In the past, much of this guidance focused on whether the combination resulted in a change of "...
The Federal Trade Commission is currently accepting public comments on an application by Teva Pharmaceutical Industries Ltd. requesting that the Commission reopen and modify its decision and order in connection with the 2012 merger of Watson Pharmaceuticals, Inc. and Actavis Inc.
We assess the performance of three hospital merger simulation methods by means of a Monte Carlo experiment. We first specify a rich theoretical model of hospital markets and use it to generate “true” price effects of a large number of hospital mergers. We then use the theoretical model...
Following a public comment period, the Federal Trade Commission has approved a final order that settles charges that Grifols S.A.’s acquisition of Biotest US Corporation is anticompetitive and violates federal antitrust law. Grifols is a global healthcare company based in Spain. Biotest US is a...
We consider whether hospital acquisitions of physicians lead to improved clinical outcomes for Medicare patients aged 65 and older. The analysis combines 2005-2012 Medicare fee-for-service and enrollment data with merger and physician affiliation information from the Levin Reports and...
The Federal Trade Commission will require Spain-based global healthcare company Grifols S.A. to divest blood plasma collection centers in three U.S. cities, among other conditions, as part of a settlement resolving charges that Grifols’ acquisition of Florida-based Biotest US Corporation is...
A Texas company that provides therapist staffing services to home health agencies, its owner, and the former owner of a competing staffing company have agreed to settle FTC charges that they agreed to reduce pay rates for therapists and invited other competitors to collude on the rates.
The Federal Trade Commission responded to the U.S. Department of Health and Human Services’ request for comment to its publication, Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. The publication seeks to “increase competition and end the gaming of regulatory processes that may keep...
Federal Trade Commission Chairman Joe Simons issued the following statement regarding the decision by the U.S. District Court for the Eastern District of Pennsylvania in the case FTC v. AbbVie. The court ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone...
In retail and health care markets, demand declines with geographic distance to the establishment, but either transport costs or preferences correlated with distance (“home bias”) could cause this decline. Using hospital choices for childbirth, we find that, after controlling for home...
The Federal Trade Commission has filed an amicus brief in Takeda Pharmaceutical Co. v Zydus Pharmaceuticals (USA) Inc., which is a patent infringement case pending before the U.S. District Court for the District of New Jersey.
Brief of the Federal Trade Commission urging the District of New Jersey to reject argument that Hatch-Waxman patent infringement suits are categorically exempt from antitrust scrutiny as potential sham litigation, because the argument is contrary to the statutory text and case law...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that a proposed merger is likely to harm competition among air ambulance transport services that transfer patients between medical facilities among the Hawaiian islands.
Federal Trade Commission Acting Chairman Maureen K. Ohlhausen released the agency’s 2017 Annual Highlights today, detailing its continued efforts to protect American consumers and promote competition without unnecessarily burdening legitimate businesses.
